The VARIANT™ II β-thalassemia Short Program is a fully-automated method for β-thalassemia and abnormal hemoglobin testing.
About
Targeted Supportive Assay
Separates and determines area percentages for
hemoglobins A2 and F and provides qualitative
determinations of abnormal hemoglobins.
Using high-performance liquid chromatography
(HPLC), the system delivers precise quantitation of
Hemoglobin A2 and F, supporting the monitoring of
patients with sickling disorders undergoing therapy.
Sample
Use of whole blood in EDTA with no preprocessing
or dilution.
TypicalUses
Clinical Assay
Targeted Therapies
Supportive Assay for BCL Proprietary Microfluidic Platforms